NC410 plus FOLFIRINOX with nivolumab, with or without ipilimumab, for untreated metastatic pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2, single-center interventional trial combines the chemotherapy regimen FOLFIRINOX with the PD-1 inhibitor nivolumab and the investigational LAIR-2 fusion protein NC410, with an optional arm including ipilimumab. The primary focus is safety monitoring and identification of any novel toxicities from the combination. Eligible participants are adults with histologically confirmed, untreated metastatic pancreatic ductal adenocarcinoma, ECOG 0–1, measurable disease, and adequate organ function. Treatments are administered per protocol at the enrolling center and patients are followed for adverse events and treatment tolerability.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.
* Metastatic histologically or cytologically confirmed pancreatic ductal adenocarcinoma.
* Have metastatic disease
* Must not have received prior systemic treatment for pancreatic cancer.
* Have measurable disease based on RECIST 1.1.
* Patients must have adequate organ and marrow function defined by study-specified laboratory tests and procedures.
* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test.
* For both Women and Men, must use acceptable form of birth control while on study.
* Must understand the study regimen, its requirements, risks and discomforts and is able and willing to sign the informed consent form in accordance with regulatory and institutional guidelines.

Exclusion Criteria:

* Have had prior chemotherapy for pancreatic cancer or prior chemotherapy within 5 years of enrollment for other cancer diagnoses.
* Has received radiotherapy for pancreatic cancer.
* Are receiving or have received any investigational agent or used an investigational device within 28 days prior to Day 1 of treatment in this study.
* Has undergone major surgery, other than diagnostic surgery (i.e. surgery done to obtain a biopsy for diagnosis or an aborted Whipple), within 28 days prior to Day 1 of treatment in this study.
* Is expected to require any other form of systemic or localized antineoplastic therapy while on study.
* Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, or anti-Lag-3 antibodies.
* Has received a live vaccine or live-attenuated vaccine within 28 days prior to the first dose of study drug.
* Prior tissue or organ allograft regardless of need for immunosuppression, including corneal allograft.
* Has uncontrolled acute or chronic medical illness.
* Has history of central nervous system (CNS) metastases and/or carcinomatous meningitis.
* Has known additional malignancy that is progressing and requires active treatment.
* Has active autoimmune disease.
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent).
* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
* Requirement for daily supplemental oxygen.
* History of interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, acute lung diseases, chronic obstructive pulmonary disease (COPD), asthma requiring medication, etc.
* Known history of human immunodeficiency virus (HIV).
* Active or chronic hepatitis B or hepatitis C.
* Unable to undergo venipuncture and/or tolerate venous access.
* Has known psychiatric or substance use disorder that would interfere with cooperation with the requirements of the trial.
* Pregnant or breastfeeding
* A WOCBP who has a positive urine pregnancy test within 72 hours prior to study drug initiation.

Where it's running

• Sidney Kimmel Comprehensive Cancer Center
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Katherine Bever, MD — SKCCC Johns Hopkins Medical Institution
• Study coordinator: Colleen Apostol, RN
• Email: GIClinicalTrials@jhmi.edu
• Phone: 410-614-3644

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer

  This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07895498

• Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer

  This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.

  Recruiting Ningbo Medical Center Lihuili Hospital · Ningbo, Zhejiang · NCT07892573

• Blood protein biomarkers to help diagnose pancreatic cancer in adults

  This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.

  Recruiting Grigore T. Popa University of Medicine and Pharmacy · Iași · NCT07875582

• Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Cancer (Phase 1)

  This early-stage study tests whether giving Lm-LLO-TT directly into the belly with low-dose gemcitabine is safe and tolerable for adults with previously treated, unresectable or metastatic pancreatic cancer.

  Recruiting Phase 1 Matter Bio, Inc. · The Bronx, New York · NCT07828236

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.